GlassScriptPhysician profile
Kevin Lee
NPI 1851894646
$4,981.28
in general payments reported to CMS, 2019-2025
22 companies · $2,832 in 2025
The $2,832 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $193 · 2022: $862 · 2023: $604 · 2024: $491 · 2025: $2,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Travel and Lodging: $1,592 · Education: $46.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.14 |
| Travel and Lodging | $1,592.10 |
| Education | $46.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,722.26 | 2022-2025 | Pascal, Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,462.12 | 2021-2025 | Triclip, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $485.75 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $400.08 | 2022-2025 | |
| Medtronic, INC. | $167.97 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan |
| Abiomed | $148.07 | 2024 | Impella |
| Stryker Corporation | $118.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.69 | 2022-2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $60.05 | 2022-2025 | |
| Philips North America LLC | $49.11 | 2022 | |
| Bridgebio Pharma, INC. | $42.27 | 2025 | Attruby |
| Amgen INC. | $39.22 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.80 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $29.35 | 2024 | Opsumit |
| Alnylam Pharmaceuticals INC. | $26.06 | 2025 | Onpattro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.70 | 2025 | |
| Heartflow, INC. | $21.60 | 2024 | |
| Esperion Therapeutics, INC. | $20.70 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $19.39 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $17.99 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Boston Scientific Corporation | $15.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.